R The EBA study of AZD5847 is planned for the future, and results from the EBA study of sutezolid are expected soon (NCT01225640,5 NCT01516203). Once the doses to be tested in later-phase studies are determined, then drug interaction studies can be considered. However, these would need to be carefully designed and take into consideration the fact that sutezolid's major metabolite circulates at hig